Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
UnitedHealth Group Inc. pages available for free this week:
- Income Statement
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Debt to Equity since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to UnitedHealth Group Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial leverage ratios illustrate a generally stable but slightly rising trend in leverage over the examined periods. Initially, the debt to equity ratio decreased from 0.7 to 0.64 in the early part of the timeline, indicating a reduction in reliance on debt relative to equity. However, from late 2021 through 2024, the ratio increased gradually, peaking near 0.87 before settling around 0.84 toward the end. This suggests a moderate increase in debt financing relative to equity.
Similarly, the debt to capital ratio remained close to 0.4 initially but displayed a gradual upward movement over time to about 0.46. This indicates a slight increase in the proportion of debt employed in the company’s capital structure, maintaining a relatively balanced use of debt and equity financing.
The debt to assets ratio started at around 0.23 and fluctuated slightly downward to about 0.20 around the end of 2021, reflecting a minor decrease in the proportion of debt used relative to total assets. However, this ratio again trended upwards through 2025, stabilizing near 0.25 to 0.26, which points to a modest increase in leverage relative to the asset base.
Examining the financial leverage ratio, which measures total assets to equity, there is a clear trend of gradual increase. Beginning at approximately 3.09, the ratio experienced small fluctuations but experienced a marked rise to around 3.49 by early 2023, before stabilizing at slightly above 3.2. This overall increase suggests that the company is progressively using more assets relative to shareholders' equity, consistent with the previously noted debt trends.
Interest coverage ratios reveal a declining ability to cover interest expenses over the period. Starting with strong coverage ratios near 15 in early 2021, the ratio fell steadily, reaching figures below 10 in 2023 and declining further to the range of 6 to 8 by 2025. This suggests that earnings available to meet interest obligations have weakened, possibly indicating increased interest expenses or moderated earnings growth relative to debt levels.
In summary, the financial data indicates a cautious increase in leverage over time, with debt ratios rising moderately across the periods analyzed. Concurrently, the decrease in interest coverage ratio calls attention to a potential increase in financial risk related to debt servicing capacity. These trends may warrant attention in financial planning and risk management strategies going forward.
Debt Ratios
Coverage Ratios
Debt to Equity
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity attributable to UnitedHealth Group
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt exhibited fluctuations over the observed periods, beginning at approximately $46.3 billion and generally trending upward. Notable increases occurred towards the end of 2022 and into 2023, reaching peaks above $70 billion. In subsequent quarters, debt levels displayed some variability but remained elevated, consistently exceeding $65 billion, with a peak nearing $81 billion in the first quarter of 2025. This indicates an overall rising leverage position over the time horizon.
- Shareholders’ Equity Attributable to UnitedHealth Group
- Shareholders’ equity showed a steady upward trend throughout the periods. Starting just above $66 billion, equity consistently increased each quarter, reaching nearly $96 billion by early 2025. The growth in equity was relatively stable, lacking any major declines, which suggests consistent generation of retained earnings and/or capital contributions supporting the company's net worth.
- Debt to Equity Ratio
- The debt to equity ratio demonstrated some variability but an overall increasing trend after mid-2021. Initially just below 0.7, the ratio dipped slightly towards the end of 2021 but rose to around 0.87 by the first quarter of 2023, indicating an increased use of debt relative to equity. While there was a modest decline following this peak, the ratio remained elevated in the range of approximately 0.83 to 0.86 through the first quarter of 2025. This upward movement aligns with the rise in total debt relative to shareholders’ equity, suggesting a moderate increase in financial leverage over the period.
Debt to Capital
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
-
The total debt exhibited an overall increasing trend throughout the observed periods from March 31, 2021, to September 30, 2025. Initially, total debt began at approximately $46.3 billion and showed fluctuations with some short-term decreases, such as in the third quarter of 2021 and late 2022. However, from early 2023 onwards, there was a consistent increase reaching above $80 billion by the third quarter of 2025. This upward movement suggests a growing reliance on debt financing over time.
- Total Capital
-
Total capital also increased steadily during the timeframe analyzed, starting around $112.7 billion and rising to nearly $176 billion by September 2025. Despite some minor quarterly variations, the general direction is upward, indicating the company has been expanding its capital base. The growth of total capital mirrors the increase in total debt, though at a moderately faster pace during some intervals.
- Debt to Capital Ratio
-
The debt-to-capital ratio, which measures the proportion of debt relative to total capital, ranged between 0.39 and 0.46 over the course of the periods. Initially, it hovered around 0.40, showing some stability in the capital structure up to early 2022. Subsequently, the ratio increased approaching 0.46 towards the end of the examined period, implying a higher leverage position. Though the ratio fluctuated slightly in intermediate quarters, the trend indicates an incremental increase in the share of debt within the capital composition.
- Insights and Implications
-
The increasing trend in total debt combined with a rising debt-to-capital ratio suggests a progressive shift towards more leverage. While total capital is growing, the debt component is increasing at a rate that elevates the leverage level. This could have implications for financial risk, interest burden, and capital costs. Monitoring future periods for any signs of stabilization or reversal in these patterns would be advisable to assess financial stability and risk management effectiveness.
Debt to Assets
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- Over the analyzed period, total debt exhibited a generally upward trajectory with some fluctuations. Starting around $46.3 billion, debt gradually increased through to the end of 2021. In 2022, debt continued to rise, peaking notably near $57.6 billion by December. The subsequent year showed continued fluctuations, with total debt ranging roughly between $62.5 billion and $73.6 billion. In the most recent quarters through 2025, total debt remained elevated, maintaining figures in the range of approximately $79.1 billion to $81.3 billion. This pattern indicates an overall increase in leverage with intermittent moderate reductions.
- Total Assets
- Total assets demonstrated a steady increase from the initial quarter through the report’s entirety. Beginning at approximately $205.2 billion, assets increased gradually into 2021 and 2022, reaching beyond $245.7 billion by the end of 2022. Growth accelerated in 2023, with total assets fluctuating around $273.7 billion to just under $284.2 billion. In 2024 and 2025, assets continued rising, ultimately surpassing $315.2 billion by the latest quarter. The consistent upward trend in assets suggests continued expansion or acquisition of resources over the period.
- Debt to Assets Ratio
- The debt to assets ratio remained relatively stable but showed a slight increasing trend over time. Initially near 0.23, the ratio dipped marginally below 0.21 during the first half of 2022, indicating a brief improvement in leverage relative to asset growth. However, from late 2022 onward, the ratio climbed steadily, peaking around 0.26 through 2024 and 2025. This upward trend implies that total debt increased at a slightly faster rate than total assets in later periods, reflecting a moderately higher financial leverage level.
- Summary of Trends and Insights
- The financial data reveals a pattern of growth in both total assets and total debt, with assets consistently outpacing initial debt increases but debt growth accelerating more noticeably in recent periods. The rising debt to assets ratio during the latter quarters points toward an increased reliance on debt financing relative to asset base expansion. The company maintains a stable leverage profile overall but with a subtle shift towards higher leverage in the final periods.
Financial Leverage
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity attributable to UnitedHealth Group
= ÷ =
2 Click competitor name to see calculations.
- Total Assets
-
Total assets demonstrate a general upward trend over the observed periods, increasing from approximately $205 billion to $315 billion. The growth shows some fluctuations with notable acceleration between late 2021 and early 2023, followed by a period of relative stabilization and moderate growth towards early 2025. This trend indicates an overall expansion in asset base, reflecting potential growth in operations, investments, or acquisitions during this timeframe.
- Shareholders’ Equity Attributable to UnitedHealth Group
-
Shareholders’ equity shows a consistent increase across the periods, rising from roughly $66 billion to nearly $96 billion. Although the growth pace varies, it remains positive throughout, suggesting retained earnings accumulation, capital injections, or a combination of both. The increases are steady without significant dips, indicating stable profitability and financial health from the perspective of equity holders.
- Financial Leverage Ratio
-
The financial leverage ratio fluctuates between approximately 2.96 and 3.49 during the analyzed time span. Initially, there is a modest decline in leverage from early 2021 to the end of that year, followed by an increase peaking around early 2023. After this peak, the ratio slightly decreases and then stabilizes in the range of 3.17 to 3.29 towards the later periods.
This behavior implies varying degrees of reliance on debt relative to equity. The general trend shows maintenance of leverage ratios above 3 in most periods, which suggests the company consistently employs significant financial leverage. The fluctuations may reflect changes in debt levels or equity growth dynamics.
- Overall Insights
-
The company’s financial position shows solid asset growth alongside strengthening equity, indicative of healthy reinvestment and profitability. The stable but moderately high financial leverage implies strategic use of debt financing, balanced with equity growth to support expansion. No extreme volatility is observed in key balance sheet metrics, which signals consistent financial management over the quarters analyzed.
Interest Coverage
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) attributable to UnitedHealth Group common shareholders | |||||||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Interest coverage
= (EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024)
÷ (Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends and fluctuations over the observed periods.
- Earnings Before Interest and Tax (EBIT)
- EBIT demonstrates a generally cyclical pattern with certain periods of growth followed by declines. The values start from a high point in the early quarters, with an initial level of 6,739 million USD, experiencing some decline towards the end of 2021, with the lowest point near 5,541 million USD. From 2022 onwards, EBIT showed a recovery and growth, rising substantially in several quarters, peaking at 8,688 million USD in September 2024. However, the last few quarters indicate a sharp decline, dipping to 4,232 million USD by the third quarter of 2025. This downward trend towards the end suggests some operational or market challenges impacting profitability.
- Interest Expense
- The interest expense exhibits a steady increasing trend over the periods. Starting at 397 million USD in the first quarter of 2021, this value consistently rises each quarter, reaching over 1,000 million USD in the majority of the 2024 and 2025 quarterly reports. This continuous growth in interest expense could imply increasing debt levels or higher borrowing costs.
- Interest Coverage Ratio
- The interest coverage ratio, which measures the ability to pay interest on outstanding debt from operational earnings, shows a declining trend over the observed period. Initially high at nearly 15 times coverage in early 2021, the ratio gradually decreases to approximately 6.5 times by late 2025. This decline reflects a relative decrease in EBIT compared to rising interest expenses, suggesting that the company's cushion to cover interest payments has weakened over time, potentially signaling increased financial risk or lower profitability robustness.
Overall, the data indicates that while operational earnings (EBIT) have experienced periods of recovery and growth, the simultaneous rise in interest expense has exerted pressure on financial metrics. The declining interest coverage ratio highlights a reduced capacity to comfortably cover interest obligations, warranting monitoring for potential credit risk or liquidity concerns if the trends persist.